These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19968016)

  • 21. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
    J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy.
    Mignot E
    Sleep Med Rev; 2004 Oct; 8(5):333-8. PubMed ID: 15336234
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of narcolepsy and other hypersomnias of central origin.
    Wise MS; Arand DL; Auger RR; Brooks SN; Watson NF;
    Sleep; 2007 Dec; 30(12):1712-27. PubMed ID: 18246981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
    Poza-Aldea JJ
    Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study.
    Mansukhani MP; Kotagal S
    Sleep Med; 2012 Jun; 13(6):606-10. PubMed ID: 22445591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study.
    Mayer G; Plazzi G; Iranzo Á; Ortega-Albás J; Quinnell T; Pesch H; Serralheiro P; Schlit AF; Wuiame D; Bentz JWG
    Sleep; 2018 Sep; 41(9):. PubMed ID: 29986085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen.
    Morse AM; Kelly-Pieper K; Kothare SV
    Pediatr Neurol; 2019 Apr; 93():39-42. PubMed ID: 30595352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects.
    Addolorato G; Lesch OM; Maremmani I; Walter H; Nava F; Raffaillac Q; Caputo F
    Expert Opin Drug Saf; 2020 Feb; 19(2):159-166. PubMed ID: 31876433
    [No Abstract]   [Full Text] [Related]  

  • 29. Sodium oxybate for narcolepsy.
    Scharf MB
    Expert Rev Neurother; 2006 Aug; 6(8):1139-46. PubMed ID: 16893342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment.
    Tittarelli R; Pichini S; Pedersen DS; Pacifici R; Moresco M; Pizza F; Busardò FP; Plazzi G
    Forensic Sci Int; 2017 May; 274():70-74. PubMed ID: 28139340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.
    Owen RT
    Drugs Today (Barc); 2008 Mar; 44(3):197-204. PubMed ID: 18536781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sodium in sodium oxybate: is there cause for concern?
    Avidan AY; Kushida CA
    Sleep Med; 2020 Nov; 75():497-501. PubMed ID: 33022487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium oxybate: a review of its use in the management of narcolepsy.
    Robinson DM; Keating GM
    CNS Drugs; 2007; 21(4):337-54. PubMed ID: 17381187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of sodium oxybate to treat narcolepsy.
    Mayer G
    Expert Rev Neurother; 2012 May; 12(5):519-29. PubMed ID: 22550980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
    Black J; Pardi D; Hornfeldt CS; Inhaber N
    Sleep Med; 2009 Sep; 10(8):829-35. PubMed ID: 19616998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem).
    Alshaikh MK; Gacuan D; George S; Sharif M; Bahammam AS
    Clin Neuropharmacol; 2011; 34(1):1-4. PubMed ID: 21206362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new indication for gamma hydroxybutyrate (Xyrem) in narcolepsy.
    Med Lett Drugs Ther; 2006 Jan; 48(1227):11-2. PubMed ID: 16444137
    [No Abstract]   [Full Text] [Related]  

  • 38. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate.
    Murali H; Kotagal S
    Sleep; 2006 Aug; 29(8):1025-9. PubMed ID: 16944670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three deaths associated with use of Xyrem.
    Zvosec DL; Smith SW; Hall BJ
    Sleep Med; 2009 Apr; 10(4):490-3. PubMed ID: 19269893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EFNS guidelines on management of narcolepsy.
    Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
    Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.